Literature DB >> 9307739

Testicular carcinoma.

A O'Callaghan1, G M Mead.   

Abstract

Testicular cancer is the commonest malignancy in young males and its incidence has more than doubled in the last 25 years. For clinical purposes, two tumour types are identified, seminoma and non-seminoma germ cell tumours (loosely known as teratomas). Stage I disease is confined to the testes and is managed surgically, with adjuvant chemotherapy or radiotherapy as appropriate. Cisplatin-based chemotherapy is the cornerstone of treatment for metastatic disease, with cure rates exceeding 80%. Early diagnosis and cure should be the aim in all patients. To this end, those with testicular symptoms should be evaluated promptly by ultrasound, and in young male patients presenting with the clinical picture of metastatic disease, germ cell tumour should top the list of differential diagnoses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307739      PMCID: PMC2431367          DOI: 10.1136/pgmj.73.862.481

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

Review 1.  Treatment of "good risk" metastatic testicular cancer.

Authors:  G C Garrow; D H Johnson
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

2.  Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone.

Authors:  L S Freedman; M C Parkinson; W G Jones; R T Oliver; M J Peckham; G Read; E S Newlands; C J Williams
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Authors:  M H Cullen; S P Stenning; M C Parkinson; S D Fossa; S B Kaye; A H Horwich; S J Harland; M V Williams; R Jakes
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

5.  Radiotherapy for stage I seminoma testis: results of treatment and complications.

Authors:  C Hamilton; A Horwich; D Easton; M J Peckham
Journal:  Radiother Oncol       Date:  1986-06       Impact factor: 6.280

6.  Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.

Authors:  G Read; S P Stenning; M H Cullen; M C Parkinson; A Horwich; S B Kaye; P A Cook
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

7.  Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients.

Authors:  S D Fosså; N Aass; O Kaalhus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-02       Impact factor: 7.038

8.  Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

Authors:  D F Bajorin; M F Sarosdy; D G Pfister; M Mazumdar; R J Motzer; H I Scher; N L Geller; W R Fair; H Herr; P Sogani
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

9.  Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors.

Authors:  E Rodriguez; S Mathew; V Reuter; D H Ilson; G J Bosl; R S Chaganti
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

Review 10.  Use of serum tumor markers in cancer diagnosis and management.

Authors:  S E Bates; D L Longo
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

View more
  1 in total

1.  Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor.

Authors:  Tatsuro Abe; Kenichi Kohashi; Junkichi Takemoto; Fumio Kinoshita; Masatoshi Eto; Yoshinao Oda
Journal:  J Cancer       Date:  2018-10-31       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.